Adverum Biotechnologies, Inc , a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases.
infoAdverum Biotechnologies is a micro cap stock with a total market cap of 168.66M.
infoThey trade on the NASDAQ and had their IPO 9 years ago.
infoAdverum Biotechnologies currently employs 123 people.
infoAs of Wednesday, Aug 23 2023, Adverum Biotechnologies’s share price is $1.67.
News Relating to Adverum Biotechnologies
Seeking Alpha
Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy
Wednesday Aug 23 2023 at 14:46
14-week data from the phase 2 LUNA study, using Ixo-vec for the treatment of patients with wet age-related macular degeneration, expected in late Q3 of 2023. Preliminary safety and efficacy data from phase 2 LUNA study, using Ixo-vec for the treatment of patients with wet age-related macular degeneration, expected Q4 of 2024. The age-related macular degeneration market is expected to reach $15.4 billion by 2032.
GlobeNewsWire
Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Monday Aug 14 2023 at 08:00
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference on Wednesday, August 16, 2023.
GlobeNewsWire
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
Wednesday May 10 2023 at 16:05
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that members of the executive team will participate in a fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference being held on Wednesday, May 17, 2023 at 3:35 p.m. ET in New York, New York.
GlobeNewsWire
Adverum Biotechnologies to Present at Upcoming Investor Conferences
Monday Feb 27 2023 at 16:05
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences:
PennyStocks
Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October
Friday Sep 30 2022 at 18:32
Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?
Zacks Investment Research
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
Thursday Sep 15 2022 at 18:28
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
GlobeNewsWire
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Thursday Sep 08 2022 at 16:05
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022.
GlobeNewsWire
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
Friday Aug 26 2022 at 16:05
REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the Gilmartin Group Inaugural Emerging Growth Company Showcase, being held on Wednesday, August 31, 2022.
GlobeNewsWire
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference
Wednesday Aug 10 2022 at 16:05
REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022.
Zacks Investment Research
Adverum (ADVM) Completes IND Amendment for Gene Therapy Study
Thursday Jul 07 2022 at 13:09
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.
PennyStocks
Top Penny Stocks To Buy Today? 3 To Watch Under $3
Thursday Jul 07 2022 at 09:30
Top penny stocks to watch this week. The post Top Penny Stocks To Buy Today?
Benzinga
Adverum Biotechnologies Cuts Workforce, Prioritizes ADVM-022
Thursday Jul 07 2022 at 08:07
Adverum Biotechnologies Inc (NASDAQ: ADVM) announced a restructuring plan, including reductions in headcount and expenses, to prioritize its clinical development of ADVM-022, a single intravitreal injection for wet age-related macular degeneration (AMD). Adverum intends these.
Zacks Investment Research
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study
Thursday Apr 07 2022 at 16:34
Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.
Benzinga
Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD
Tuesday Dec 21 2021 at 12:42
Adverum Biotechnologies Inc (NASDAQ: ADVM) plans to conduct a Phase 2 trial of ADVM-022 in wet AMD at 2 X 10^11 vg/eye dose and a new lower 6 X 10^10 vg/eye dose, with three new enhanced steroid prophylaxis regimens in wet age-related macular degeneration (wet AMD). The enhanced steroid prophylaxis regimens include topical, intravitreal (IVT), and a combination of systemic and local steroids.
PennyStocks
4 Short Squeeze Penny Stocks To Watch Right Now
Monday Dec 13 2021 at 15:47
4 penny stocks with high short interest or low floats to watch this week The post 4 Short Squeeze Penny Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts
Sunday Oct 10 2021 at 10:45
Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?
GlobeNewsWire
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
Saturday Oct 09 2021 at 11:17
— Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD — — Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD —
Pulse2
ADVM Stock: Why It Increased Today
Monday Oct 04 2021 at 06:11
The stock price of Adverum Biotechnologies, Inc. (Nasdaq: ADVM) increased by over 10% pre-market today. This is why it happened.
PennyStocks
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
Sunday Oct 03 2021 at 10:45
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GlobeNewsWire
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections
Friday Oct 01 2021 at 16:00
— Results featured in a presentation today at the Retina Society’s 54 th Annual Scientific Meeting — — Robust aflibercept protein expression sustained through 2 years —
GlobeNewsWire
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
Monday Sep 27 2021 at 09:00
REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new clinical data on ADVM-022 intravitreal (IVT) injection gene therapy from the OPTIC trial in wet age-related macular degeneration (wet AMD) and the INFINITY trial in diabetic macular edema (DME) at upcoming medical conferences. Adverum is planning clinical development of ADVM-022 at the 2 x 10^11 vg/eye and a lower dose in patients with wet AMD. As previously disclosed, the company is no longer planning to develop ADVM-022 in DME.
GlobeNewsWire
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
Monday Aug 23 2021 at 09:00
REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D., has been appointed senior vice president, head of regulatory affairs. Reporting directly to Laurent Fischer, M.D., Adverum’s president and chief executive officer, Dr. Wang will lead regulatory strategies and execution for the company’s product pipeline. He brings more than 17 years of global regulatory experience, including a decade in gene therapy that includes the submission and approval for LUXTURNA®, the first gene therapy targeting a genetic disease that received regulatory approval in both the U.S. and EU.
GlobeNewsWire
Adverum Announces Changes to Management Team
Thursday Jun 24 2021 at 16:05
— Christopher J. DeRespino appointed acting CFO — — Peter Soparkar appointed COO —
GuruFocus
A Trio of Net Current Asset Value Stock Picks
Wednesday Jun 09 2021 at 12:07
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the share prices to near or above the liquidation value.
The Motley Fool
Why Adverum Biotechnologies Stock Sank in May
Monday Jun 07 2021 at 10:00
The uncertainty over the biotech’s lead clinical asset weighed on its shares last month.
Zacks Investment Research
Are Options Traders Betting on a Big Move in Adverum (ADVM) Stock?
Tuesday May 18 2021 at 09:46
Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.
Zacks Investment Research
Adverum Biotechnologies (ADVM) is Oversold: Can It Recover?
Monday May 17 2021 at 08:16
Adverum Biotechnologies (ADVM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Business Wire
The Sonic Fund II, L.P. Comments on Preliminary Voting Results of Adverum Annual Meeting
Wednesday May 12 2021 at 15:17
HONOLULU–(BUSINESS WIRE)–The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today issued the following statement regarding the preliminary voting results from the Company’s 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”). “We wish to express our sincere gratitude to the stockholders who supported our push for change and an improved Board at A
GlobeNewsWire
Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
Wednesday May 12 2021 at 13:05
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that, based on a preliminary vote count provided by its proxy solicitors following its 2021 Annual Meeting of Stockholders, stockholders have voted to re-elect all three of Adverum’s highly qualified director nominees – Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. – to the Adverum Board of Directors, ratified the selection of Ernst & Young LLP as independent auditors and approved, on an advisory basis, the compensation of Adverum’s named executive officers.
Business Wire
The Sonic Fund II, L.P. Issues Statement to Adverum Stockholders
Tuesday May 11 2021 at 15:15
HONOLULU–(BUSINESS WIRE)–The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today issued the following statement regarding the Company’s upcoming 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”), which will be held on Wednesday, May 12, 2021. “It has come to our attention that one or more Adverum stockholders were left with the impression, fol
Adverum Biotechnologies Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Adverum Biotechnologies’s Altman Z-score is -5.45 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Adverum Biotechnologies Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has bought $145.49K of common stock in Adverum Biotechnologies on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Adverum Biotechnologies’s Income Quality of 0.72 is in line with its Industry Group of 0.69 (4.3% greater)
Adverum Biotechnologies’s Income Quality of 0.72 is in line with its Major Industry Group of 0.71 (1.4% greater)
Adverum Biotechnologies’s Income Quality of 0.72 is in line with its Sector of 0.75 (-4.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Adverum Biotechnologies’s Current Ratio of 3.31 is lower than its Industry Group of 4.76 (-30.5% lower)
Adverum Biotechnologies’s Current Ratio of 3.31 is lower than its Major Industry Group of 4.32 (-23.4% lower)
Adverum Biotechnologies’s Current Ratio of 3.31 is greater than its Sector of 2.6 (27.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-1.26 & -1.27)
Cannot compare a negative PE Ratio (-1.26 & -1.1)
Cannot compare a negative PE Ratio (-1.26 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Adverum Biotechnologies’s PB Ratio of 1.29 is in line with its Industry Group of 1.34 (-3.7% lower)
Adverum Biotechnologies’s PB Ratio of 1.29 is in line with its Major Industry Group of 1.4 (-7.9% lower)
Adverum Biotechnologies’s PB Ratio of 1.29 is lower than its Sector of 1.62 (-20.4% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Adverum Biotechnologies’s ROE of -1.02 is lower than its Industry Group of -0.44 (-131.8% lower)
Adverum Biotechnologies’s ROE of -1.02 is lower than its Major Industry Group of -0.38 (-168.4% lower)
Adverum Biotechnologies’s ROE of -1.02 is lower than its Sector of -0.03 (-3300.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Adverum Biotechnologies’s ROCE of -0.69 is lower than its Industry Group of -0.42 (-64.3% lower)
Adverum Biotechnologies’s ROCE of -0.69 is lower than its Major Industry Group of -0.37 (-86.5% lower)
Adverum Biotechnologies’s ROCE of -0.69 is lower than its Sector of -0.04 (-1625.0% lower)
Derived from SEC.GOV filing dataopen_in_new